Lonza’s API manufacturing facility expansion in Nansha starts commercial operation
Pharma Supply Chain People Moves
Lonza Appoints Daniel Palmacci as President of Cell & Gene Division
In response to rising demand for inhalable treatments geard toward respiratory conditions, the company is adding capabilities and capacity at its Tampa site.
Lonza Introduces X-Ray Powder Diffraction Capability at Monteggio Site
Lonza debuts first multimode reader to streamline quantitative endotoxin detection
Lonza posts double-digit growth in H1 thanks to strong pharma demand
Lonza Continues to Lead the Market with Innovative Hard Empty Capsules
Lonza has launched the PyroCell Monocyte Activation Test - Human Serum System (PyroCell MAT HS System), which uses human serum instead of fetal bovine serum. This new in vitro pyrogen testing system exhibits enhanced sensitivity for detection of non-endotoxin pyrogens as well as reduced interferences from complex drug products such as biologics-based pharmaceuticals.
Lonza opens early-phase development and manufacturing favcility in Oregon